Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Also, the revs from 420cloud.com and 420jobsearc haven't even been factored into MCIG's FUTURE financials.. btw- I bet you also think ziprecruiter.com is in on MCIGS scam too? lol
looks to me as there was a deal brokered by a third party company in the sale of 420cloud.com was that so hard to figure out..
thank you goodibag !!
AGREED !!
why purchase or take over a shell if you don't plan on following the guidelines?? doesn't make any sense to me !! Crossing my fingers for ALL the longs..
goodibag,
do you know for sure this week we will see financials or do you think next Tuesday bc its a short week?
well stated les
agreed !!
profitable and acquiring multiple companies to GROW the bottom line in the near future, this company is rocking and rolling the mj industry!!
Blullish,
ill check it out !!
Thank you!!
Check out CRYO on barchart.com
Barchart Technical Opinion
STRONG BUY
The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.
Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.
https://www.barchart.com/stocks/quotes/CRYO
Check out CRYO on barchart.com
Barchart Technical Opinion
STRONG BUY
The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.
Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.
https://www.barchart.com/stocks/quotes/CRYO
If you like Stem Cell companies check out CRYO 3rd quarter result just came out last week. Very LOW FLOAT might be a GREAT time to take a position imo .. PLEASE do your own DD !!
http://www.otcmarkets.com/stock/CRYO/news
CRYO releases 10Q here is a quick overview of news late last week.
http://www.otcmarkets.com/stock/CRYO/news
- The Company was profitable for the first time for the quarter. For Q3 2017, the Company showed Net Income of $11,532.
- The Company's Total Revenue increased 269%; from $438,304 to $1,181,979, for the nine month period Fiscal 2017 versus Fiscal 2016.
- Cost of Revenue as a percentage of Revenue decreased from 56% to 35%, for the nine month period in Fiscal 2017 versus Fiscal 2016.
- Professional fees (principally legal and accounting) decreased to $55,898 in the nine month period in Fiscal 2017 as compared to $107,566 in Fiscal 2016.
- The Company's cash position increased to $91,494 for the period ended June 30, 2017 as compared to $37,313 for Fiscal 2016.
Barchart.com opinion https://www.barchart.com/stocks/quotes/CRYO
Barchart Technical Opinion
STRONG BUY
The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.
Longer term, the trend strength is in the Top 1%. Long term indicators fully support a continuation of the trend.
The market is in highly overbought territory. Beware of a trend reversal.
Full story below
American CryoStem Corporation Announces Financial Results for Q3 Fiscal 2017
EATONTOWN, NJ / ACCESSWIRE / August 22, 2017 / American CryoStem Corporation (OTC PINK: CRYO) a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today released summary financial highlight information regarding the Company's nine months ending June 30, 2017 versus the same nine month period in fiscal 2016, http://www.americancryostem.com/sec-filings:
- The Company was profitable for the first time for the quarter. For Q3 2017, the Company showed Net Income of $11,532.
- The Company's Total Revenue increased 269%; from $438,304 to $1,181,979, for the nine month period Fiscal 2017 versus Fiscal 2016.
- Cost of Revenue as a percentage of Revenue decreased from 56% to 35%, for the nine month period in Fiscal 2017 versus Fiscal 2016.
- Professional fees (principally legal and accounting) decreased to $55,898 in the nine month period in Fiscal 2017 as compared to $107,566 in Fiscal 2016.
- The Company's cash position increased to $91,494 for the period ended June 30, 2017 as compared to $37,313 for Fiscal 2016.
Anthony Dudzinski, COO stated, "We have seen a continued increase in our processing volume revenue for our ATGRAFT tissue storage platform, as well as from individuals storing their stem cells during the quarter ended June 30, 2017. This revenue contributed to the Company's outstanding results for the nine month period. We continue to expand our domestic physician network base and seek new international territories with licensees seeking to establish our adipose tissue (fat) based collect-process-store and stem cell platform in their country."
About American CryoStem Corporation
American CryoStem Corporation (OTC PINK: CRYO) was founded in 2008, and has evolved to become a biotechnology pioneer, standardizing adipose tissue derived technologies (Adult Stem Cells) for the fields of Regenerative and Personalized Medicine. The Company operates a state-of-art, FDA-registered, clinical laboratory in New Jersey and licensed laboratories in Hong Kong, China and Tokyo, Japan, operating on our proprietary platform, dedicated to the collection, processing, bio-banking, culturing and differentiation of adipose tissue (fat) and adipose derived stem cells (ADSCs) for current or future use in regenerative medicine. CRYO maintains a strategic portfolio of intellectual property (IP) that surrounds our proprietary technology which supports a growing pipeline of stem cell applications and biologic products. We are leveraging our proprietary platform and a developed product portfolio to create a domestic and global footprint of licensed laboratory affiliates, physicians networks and research organizations who purchase tissue collection, processing and storage consumables from our Company. Our laboratory stem cell bank/line products are characterized adult human Mesenchymal Stem Cell (MSC's) derived from adipose tissue that work in conjunction with our 13 patented (non-animal) medium lines. The Company's R&D efforts are focused on university and private collaborations to discover, develop and commercialize ADSC therapies by utilizing our standardized collection-processing-storage methodology and laboratory products combined with synergistic technologies to create jointly developed regenerative medicine applications and intellectual property.
For further detailed Corporate or Regenerative Medicine information please visit:
www.americancryostem.com, request by email at info@americancryostem.com or phone 732-747-1007
SOURCE: American CryoStem Corporation
© Copyright © 2017 Accesswire. All rights reserved.
If you like Stem Cell companies check out CRYO 3rd quarter result just came out last week. Very LOW FLOAT might be a GREAT time to take a position imo .. PLEASE do your own DD !!
http://www.otcmarkets.com/stock/CRYO/news
CRYO releases 10Q here is a quick overview of news late last week.
http://www.otcmarkets.com/stock/CRYO/news
- The Company was profitable for the first time for the quarter. For Q3 2017, the Company showed Net Income of $11,532.
- The Company's Total Revenue increased 269%; from $438,304 to $1,181,979, for the nine month period Fiscal 2017 versus Fiscal 2016.
- Cost of Revenue as a percentage of Revenue decreased from 56% to 35%, for the nine month period in Fiscal 2017 versus Fiscal 2016.
- Professional fees (principally legal and accounting) decreased to $55,898 in the nine month period in Fiscal 2017 as compared to $107,566 in Fiscal 2016.
- The Company's cash position increased to $91,494 for the period ended June 30, 2017 as compared to $37,313 for Fiscal 2016.
Barchart.com opinion https://www.barchart.com/stocks/quotes/CRYO
Barchart Technical Opinion
STRONG BUY
The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.
Longer term, the trend strength is in the Top 1%. Long term indicators fully support a continuation of the trend.
The market is in highly overbought territory. Beware of a trend reversal.
Full story below
American CryoStem Corporation Announces Financial Results for Q3 Fiscal 2017
EATONTOWN, NJ / ACCESSWIRE / August 22, 2017 / American CryoStem Corporation (OTC PINK: CRYO) a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today released summary financial highlight information regarding the Company's nine months ending June 30, 2017 versus the same nine month period in fiscal 2016, http://www.americancryostem.com/sec-filings:
- The Company was profitable for the first time for the quarter. For Q3 2017, the Company showed Net Income of $11,532.
- The Company's Total Revenue increased 269%; from $438,304 to $1,181,979, for the nine month period Fiscal 2017 versus Fiscal 2016.
- Cost of Revenue as a percentage of Revenue decreased from 56% to 35%, for the nine month period in Fiscal 2017 versus Fiscal 2016.
- Professional fees (principally legal and accounting) decreased to $55,898 in the nine month period in Fiscal 2017 as compared to $107,566 in Fiscal 2016.
- The Company's cash position increased to $91,494 for the period ended June 30, 2017 as compared to $37,313 for Fiscal 2016.
Anthony Dudzinski, COO stated, "We have seen a continued increase in our processing volume revenue for our ATGRAFT tissue storage platform, as well as from individuals storing their stem cells during the quarter ended June 30, 2017. This revenue contributed to the Company's outstanding results for the nine month period. We continue to expand our domestic physician network base and seek new international territories with licensees seeking to establish our adipose tissue (fat) based collect-process-store and stem cell platform in their country."
About American CryoStem Corporation
American CryoStem Corporation (OTC PINK: CRYO) was founded in 2008, and has evolved to become a biotechnology pioneer, standardizing adipose tissue derived technologies (Adult Stem Cells) for the fields of Regenerative and Personalized Medicine. The Company operates a state-of-art, FDA-registered, clinical laboratory in New Jersey and licensed laboratories in Hong Kong, China and Tokyo, Japan, operating on our proprietary platform, dedicated to the collection, processing, bio-banking, culturing and differentiation of adipose tissue (fat) and adipose derived stem cells (ADSCs) for current or future use in regenerative medicine. CRYO maintains a strategic portfolio of intellectual property (IP) that surrounds our proprietary technology which supports a growing pipeline of stem cell applications and biologic products. We are leveraging our proprietary platform and a developed product portfolio to create a domestic and global footprint of licensed laboratory affiliates, physicians networks and research organizations who purchase tissue collection, processing and storage consumables from our Company. Our laboratory stem cell bank/line products are characterized adult human Mesenchymal Stem Cell (MSC's) derived from adipose tissue that work in conjunction with our 13 patented (non-animal) medium lines. The Company's R&D efforts are focused on university and private collaborations to discover, develop and commercialize ADSC therapies by utilizing our standardized collection-processing-storage methodology and laboratory products combined with synergistic technologies to create jointly developed regenerative medicine applications and intellectual property.
For further detailed Corporate or Regenerative Medicine information please visit:
www.americancryostem.com, request by email at info@americancryostem.com or phone 732-747-1007
SOURCE: American CryoStem Corporation
© Copyright © 2017 Accesswire. All rights reserved.
thank you for the update !! how much longer do they think shareholders will wait? lol
has anyone heard from the CEO via email or anything else this week?
It will be nice once revenue comes in from 420cloud and 420jobsearch !!
CRYO nice little pullback.
Nice volume and ended the day GREEN!! imo GOING HIGHER !!
wow, its pretty quiet on the board today..lol
looks like a good time to pick more shares up !!
thats a ton !!
bmg,
fins look great and going HIGHER !!
wow, 3.2 mill... you will be laughing all the way to the bank when they come out w/ 10k..etc..
crash and burn ?? lol
CRYO still holding above 1.00 and looking good..
its funny when you look back at some of the press release they were killing it and it amazes me that people would think they'd be bad fins..lol
MCIG running on ALL cylinders!!
I agree with you !!
Goodibag,
Im in and going long but they NEED to release something today !!
Looks like the market and mm's likes the fins... go HIGHER !!
mCig, Inc., Releases Annual Audit Report for Fiscal Year 2017, Ending April 30, 2017
Reports net earnings of $1.5 million
Record year with 277% revenue increase over Fiscal Year 2016
LAS VEGAS, NV--(Marketwired - Aug 28, 2017) - mCig Inc., (OTCQB: MCIG), announced today that it has filed with the U.S. Securities and Exchange Commission its Annual Report on Form 10-K for the year ended April 30, 2017. The report is available on MCIG's website at www.mciggroup.com.
MCIG recorded a record-breaking year. MCIG saw tremendous growth in its revenue, net earnings, cash position, and balance sheet. Highlights of the Annual Report include:
Our revenue from continuing operations for FY2017 was $4,777,072 compared to $1,723,421 from the previous year, an increase of $3,053,651 or approximately 277%
Our gross profit for FY2017 was $1,896,029 compared to $290,773 from the previous year
Our operating expenses decreased by $732,688 to $967,040 for FY2017, from $1,699,728 for the previous year
Our net operating income increased by $2,337,944 to $929,989 for FY2017 from a net loss of $1,408,955 for the previous year.
MCIG recorded a $1,527,352 net profit, $1,539,233 EBITDA, and a $32,685 adjusted net income.
MCIG completed 7 acquisitions throughout the year and sold one asset.
"This has been a record year for mCig and its shareholders. MCIG has seen tremendous improvements in revenue, gross profits, net profits, cash position, CAGR, and shareholder value. MCIG has done this with no toxic debt. With our new and innovative solutions that are projected to have a significant impact on our future financial statements rolling out shortly, the MCIG story will continue to be exciting," says Paul Rosenberg, the company's Chief Executive Officer. He went on to say, "We expect to continue to see organic and acquisition revenues to grow, strengthening the MCIG name in the cannabis industry. I encourage all our shareholders to download our Annual Report to review where we came from and see where we are headed."
mid day still GREEN w/ anticipation of good financials coming out
CRYO 1.00 by 1.01 looking good and a ton of volume today
Correct !!
your statement, "some of you better open your eyes. and get the heck away from this one. because by next spring Canada legalization goes across their landscape.
as is."
btw- There are Canadian companies BUYING American mj companies to have a foot hold in the US market, so i'd say if there is something to be worried about would be a Canadian company buying MCIG.. so either way its a win win imo... IMO most people dont trust the Canadian stock market..
Btw- i dont know any other Canadian companies who have deals with zip recruiter ..
I have no idea.. i hope today..
if MCIG doesn't have any snap or boom? why are you on the board?
as i stated before, IMO MCIG will BOOM again !!
wow, already back up to .91 by 1.00 nice volume !!